© 2021 MJH Life Sciences and HCPLive. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive. All rights reserved.
January 16, 2021
There is currently no approved treatment for fragile X syndrome.
Current estimates indicate that non-adherence to stimulants is as high as 87%.
New research expands on the understood link between sleep and ADHD-related behavior, and gives clinicians new therapeutic targets.
Though the correlation is concerning for at-risk groups, experts believe it could inform individualized psychiatric care during crises.
The APSARD study finds that most neuropsychological assessment scores did not differ significantly between both in-person and virtual visit modalities.
Methylphenidate has shown promising boosting morning function in pediatric patients with ADHD.
Both monotherapy and combination of the unique regimen was shown to improve manic and depressive status at 12 weeks.
The Child Behavior Checklist may provide invaluable information to clinicians regarding the type and severity of comorbid psychopathologies.
The treatment improves morning function for adolescent ADHD patients.
The indication is the first of its kind for the rare, sometimes quickly fatal disease.